Henan Taifeng Pharmaceutical Technology Group Co., Ltd.

The primary study objective was to evaluate the pharmacokinetic parameters of the investigational pioglitazone-metformin tablets (strength: 15 mg/500 mg, licensed by Zhengzhou Taifeng Pharmaceutical Co., Ltd.) compared with the reference formulation, pioglitazone-metformin tablets (Metact LD®, strength: 15 mg/500 mg, licensed by Takeda Pharmaceutical Company Limited), in healthy volunteers after a single oral dose under fasting conditions, and to assess the bioequivalence of the two formulations. The secondary study objective was to evaluate the safety of the investigational pioglitazone-metformin tablets (strength: 15 mg/500 mg) compared with the reference formulation, pioglitazone-metformin tablets (Metact LD®, strength: 15 mg/500 mg), in healthy volunteers.

The primary study objective was to evaluate the bioequivalence of Shionogi Inc.'s licensed Luqubopa tablets (3 mg, trade name: Mulpleta®) as the reference formulation and Zhengzhou Taifeng Pharmaceutical Co., Ltd.'s Luqubopa tablets (3 mg) as the test formulation in a single-center, randomized, open-label, two-dose, single-dose, two-sequence, two-period, double-crossover clinical study in the fed state. The secondary study objective was to observe the safety of the test and reference formulations in healthy Chinese volunteers.